Process for preparing synthetic matrix metalloprotease inhibitors

US5892112A · kind A · utility

Assignees

• Glycomed Incorporated · US
• University of Florida Foundation, Incorporated · US

Inventors

• Daniel Levy · San Mateo, US
• Damian Wojciech Grobelny · Melbourne, AU
• Cho Tang · Moraga, US
• Kevin R. Holme · Alameda, US
• Richard E. Galardy · Lexington, US
• Gregory S. Schultz · Gainesville, US
• Asaad Nematalia · Alameda, US
• John H. Musser · Alameda, US

Key dates

• Filing date: Jan 21, 1994
• Grant date: Apr 6, 1999
• Expiry date: Jan 21, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.